Ms. Angela Joo-Hyun Kang, Founder and Executive President, Global Competitiveness Empowerment Forum (GCEF) was invited as a keynote speaker by headquarter of Ono Pharmaceutical Co., Ltd. for the CSR lecture to its executives.
Moderated by Mr. Jun, Kuriha, one of board members as a Non-Executive Director of Ono, the CSR lecture was held on November 11, 2016 at its headquarter premise in Osaka, Japan with presence of about 50 top executives including Ono's founder's family member as one of board members, Mr. Kei Sano, Executive Director of Corporate Management and one of board members, Mr. Masaki Itoh, Director of Corporate Planning, Mr. Nobuyuki Iwai, Deputy Senior Director of Corporate Planning and CSR Promotion Dept., and Dr. Toichi Takino, Executive Director of Corporate Development & Strategy.
The topic was focus on CSR, sustainablity, GloCallization, and UN Sustainable Development Goals, specific to pharmaceutical sector.
With a history of approximately 300 years for new drug development, Ono Pharmaceutical Co., Ltd. is a R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. It focuses especially on the diabetes and oncology areas. With its capital of 17,358 million Japanese Yen, in May 2014, the FDA granted Opdivo Breakthrough Therapy Designation for the treatment of patients with Hodgkin lymphoma. Opdivo is a PD-1 immune checkpoint inhibitor approved in Japan for the treatment of patients with unresectable melanoma, making it the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world, and is being developed in multiple tumor types in more than 35 clinical trials.
Web site of Ono Pharmaceutical Co., Ltd. : http://www.ono.co.jp/eng